Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.62 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 3/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5415065 | 0.90 | ROCK2 (0.65) | ROCK2ROCK1MAPK14MAOBCYP3A4 | |
| SCHEMBL5417370 | 0.90 | ROCK2 (0.65) | ROCK2ROCK1MAPK14RIPK2MAOB | |
| SCHEMBL5419135 | 0.89 | ROCK2 (0.64) | ROCK2ROCK1MAPK14MAOBCYP3A4 | |
| SCHEMBL5412576 | 0.89 | ROCK2 (0.64) | ROCK2ROCK1MAPK14MAOBCYP3A4 | |
| SCHEMBL5412581 | 0.89 | MAPK14 (0.62) | ROCK2ROCK1MAPK14MAOB | |
| SCHEMBL5405569 | 0.87 | ROCK2 (0.57) | ROCK2ROCK1MAPK14NAMPTIGF1R | |
| SCHEMBL5415131 | 0.86 | ROCK2 (0.62) | ROCK2ROCK1MAPK14MAOB | |
| SCHEMBL5404301 | 0.86 | ROCK2 (0.62) | ROCK2ROCK1MAPK14NAMPTMAOB | |
| SCHEMBL5407420 | 0.85 | ROCK2 (0.61) | ROCK2ROCK1MAPK14NAMPTMAOB | |
| SCHEMBL5407427 | 0.85 | ROCK2 (0.61) | ROCK2ROCK1MAPK14NAMPTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ROCK2 2/4885ROCK1 1/4885MAPK14 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.